Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
about
Interventions for preventing neuropathy caused by cisplatin and related compoundsInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing neuropathy caused by cisplatin and related compoundsInterventions for preventing oral mucositis for patients with cancer receiving treatmentInterventions for preventing neuropathy caused by cisplatin and related compoundsResidual neurotoxicity in ovarian cancer patients in clinical remission after first-line chemotherapy with carboplatin and paclitaxel: the Multicenter Italian Trial in Ovarian cancer (MITO-4) retrospective study.Vincristine-induced peripheral neuropathy in pediatric cancer patientsChemotherapy-induced neuropathies-a growing problem for patients and health care providersChemotherapy- and radiotherapy-induced oral mucositis: review of preventive strategies and treatment.Gastrointestinal permeability in ovarian cancer and breast cancer patients treated with paclitaxel and platinumThe PI3K/Akt pathway upregulates Id1 and integrin α4 to enhance recruitment of human ovarian cancer endothelial progenitor cells.Efficacy and tolerability of amifostine in elderly cancer patientsPathophysiology of Chemotherapy-Induced Peripheral Neuropathy.Oral mucositis induced by anticancer treatments: physiopathology and treatments.Clinical experience with nanoparticle albumin-bound paclitaxel, a novel taxane anticancer agent, and management of adverse events in females with breast cancerPlatinum-induced neurotoxicity and preventive strategies: past, present, and futureContemporary quality of life issues affecting gynecologic cancer survivors.Proposed medications for taxane-induced myalgia and arthralgia (Review).New Insights into Potential Prevention and Management Options for Chemotherapy-Induced Peripheral Neuropathy.Mutant p53 promotes ovarian cancer cell adhesion to mesothelial cells via integrin β4 and Akt signalsPreventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: results of meta-analyses.Quality of life considerations in gynecologic cancer. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.Pathobiology of cancer chemotherapy-induced peripheral neuropathy (CIPN).Strategies for optimizing the response of cancer and normal tissues to radiation.Evaluation of current and upcoming therapies in oral mucositis prevention.Radiobiological modifiers in clinical radiation oncology: current reality and future potential.Protective effect of amifostine on busulfan induced DNA damage in human hepatoma cells.Over-expression of COX-2 induces human ovarian cancer cells (CAOV-3) viability, migration and proliferation in association with PI3-k/Akt activation.Risk-reduction and treatment of chemotherapy-induced peripheral neuropathy.In Search of a Gold Standard Patient-Reported Outcome Measure for Use in Chemotherapy- Induced Peripheral Neuropathy Clinical Trials.
P2860
Q24197763-D436F9C0-EA96-4A73-A79D-2AFA04AC4C0EQ24235217-8AFEFC20-FD7A-4892-BD12-5BAD434E0FECQ24235482-740CE1BA-AF4C-4625-BBAB-C51B9E20DA43Q24236661-8FBD2D1B-494A-420E-9B4B-60D47E956C9BQ24243046-E71CEA2D-DE3C-4B38-AB3A-764C4E74A868Q24246530-99300308-D30F-4E45-BEF3-61D158A64365Q25257587-3D67BEAD-4280-4055-9F2B-D8F0895E56C5Q28078232-8D024822-8A31-499A-8ED0-71F09485BB65Q28818565-DECE8678-40A6-4A11-A95C-337298690E26Q33217865-5D9E4D72-03CB-43F7-8289-A4AC8A8C19DBQ33293726-AA9B361C-C9DD-4901-9026-13BE4E317398Q33675431-B7CD0392-0C22-45A1-BE94-0092EB7120FDQ33738758-28DDD407-63DA-4974-B385-80EDB82A0ABFQ33744706-36012B40-8A19-46FA-A0F1-AB32D33D68AAQ35166803-C33BE348-2B0D-49E8-A068-AEE2F1517E0DQ35167769-B98962D6-94A8-45F8-8105-806FF770A60FQ35345734-2483A466-B051-4CBB-8125-C536C562157EQ36067725-3E404383-EFEB-48CD-91C0-EA8D16EFBDE4Q36084331-5BE87B7D-0205-446F-9F49-479835FFE973Q36226275-28F72BB8-30EA-42FA-B598-8459864DE87AQ36292196-5F95DF92-A139-45BF-9BC4-C89CF0B19EB8Q36544184-85801E80-8E3C-40C5-9EEA-75A733773E56Q36679733-9635FCE7-DF01-47BC-8A9D-060B75ED17C5Q37399781-203941D4-9E2A-47D7-9CAC-C77A1440FC11Q37531724-87268D07-E9C9-445C-9A36-84FBF61CE9EEQ37818225-D598EFE2-F06F-4BDC-9484-24268B7E33AFQ38294597-405D817C-160C-4562-8858-C6E8B3D3A027Q38738226-9AC9FB51-AC92-4B61-9B77-E0453EE780DAQ39938948-B7FFF4BB-3F71-49AB-9BD4-66FAB2EB2D27Q47552411-DD9FDAF9-327D-4378-81C7-FC2E68E05A10Q55241487-FBF4C85E-246C-4892-919A-8996C3C9553F
P2860
Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients.
description
2003 nî lūn-bûn
@nan
2003 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年論文
@yue
2003年論文
@zh-hant
2003年論文
@zh-hk
2003年論文
@zh-mo
2003年論文
@zh-tw
2003年论文
@wuu
name
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@ast
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@en
type
label
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@ast
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@en
prefLabel
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@ast
Phase III multicenter randomiz ...... py in ovarian cancer patients.
@en
P2093
P50
P921
P356
P1433
P1476
Phase III multicenter randomiz ...... apy in ovarian cancer patients
@en
P2093
G Di Vagno
L Manzione
Multicenter Italian Trials in Ovarian Cancer invesitgators
R Biamonte
P304
P356
10.1093/ANNONC/MDG301
P577
2003-07-01T00:00:00Z